1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Concord Biotech Limited

Concord Biotech Limited

CONCORDBIO.BO
Concord Biotech LimitedIN flagBombay Stock Exchange
1,273.55
INR
+12.75
- -
133.06BMarket Cap
Concord Biotech Limited
CONCORDBIO.BO
(Bombay Stock Exchange)

Recent

price

1,273.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
FRC
47.62
57.74
67.72
79.4
95.4
114.7
100.19
100.74
Revenue per Share
16.16
22.45
16.72
22.95
29.45
35.52
24.78
24.79
Basic EPS, GAAP
-0.06
-3.57
4.97
9.65
17.18
12.74
16.31
- -
Free Cash Flow per Basic Share
7.7
0.55
6.74
5.12
6.83
8.75
10.63
- -
Dividend per Share
62.91
84.81
94.74
112.68
135.3
162.62
0.99
1
Book Value per Share
73.62
94.91
105.11
123.29
145.9
173.14
191.22
192.27
Tangible Book Value per Share
105
105
105
105
105
105
105
105
Basic Weighted Avg Shares
4,982
6,041
7,084
8,306
9,981
12,001
10,549
10,549
Sales/Revenue/Turnover
39.07
50.2
33.33
36.69
38.7
37.66
27.77
27.77
Operating Margin (%)
212
275
500
540
536
544
745
745
Depreciation Expense
1,691
2,349
1,749
2,401
3,081
3,716
2,609
2,596
Net Income, GAAP
20.84
24.89
26.35
25.44
25.32
24.85
24.78
24.78
Effective Tax Rate (%)
33.95
38.89
24.69
28.9
30.87
30.97
24.73
24.6
Profit Margin (%)
4,235
5,014
4,775
5,359
7,541
9,512
10,810
10,810
Working Capital
385
579
316
64
19
6
14
14
LT Debt
7,702
9,994
11,032
12,900
15,266
18,127
20,151
20,151
Total Equity
- -
23.85
15.44
18.22
20.1
20.2
11.48
11.48
Return on Invested Capital (%)
- -
27.91
17.63
21.51
23.53
23.77
30.64
30.32
Return on Capital (%)
- -
30.4
18.63
22.13
23.75
23.85
30.48
30.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
10
- -
9
LT Borrowings
- -
- -
- -
LT Finance Leases
6
- -
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
- -
105
Market Capitalization
172,393
140,773
106,380

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10,798
- -
12,501
Cash, Cash Equivalents & STI
3,814
- -
4,409
Accounts Receivable, Net
3,968
- -
4,602
Inventories
2,763
- -
3,264
Total Current Liabilities
1,550
- -
1,691
Payables & Accruals
- -
- -
- -
ST Debt
10
- -
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.11%
11.17%
Free Cash Flow
- -
-12.76%
28.79%
Net Income, GAAP
- -
6.17%
-29.8%
Sales/Revenue/Turnover
- -
12.57%
-12.1%
Total Cash Common Dividend
- -
239.13%
22.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,948
2,623
2,408
3,001
9,981
2025
2,158
3,102
2,442
4,299
12,001
2026
2,040
2,471
2,778
3,261
10,549

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.21
7.74
7.41
- -
29.45
2025
5.7
9.15
7.26
13.42
35.52
2026
4.21
6.03
6.08
8.46
24.78

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6.83
2025
- -
- -
- -
- -
8.75
2026
- -
- -
- -
- -
10.63
Similar Companies
Kiromic BioPharma, Inc. (KRBP)
Gc Cell Corp. (144510.KQ)
ABVC BioPharma, Inc. (ABVC)
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)
PCI Biotech Holding ASA (PCIB.OL)
Helix BioPharma Corp. (HBP.TO)
Business
Concord Biotech Limited, an India-based biopharmaceutical company founded in 1984 and headquartered in Ahmedabad, Gujarat, researches, develops, manufactures, markets and sells fermentation-based active pharmaceutical ingredients, finished dosage formulations and contract research and manufacturing services internationally. The company produces APIs across key therapeutic segments including immunosuppressants such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus; oncology products such as temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone and everolimus premix; anti-bacterials such as mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride and teicoplanin; anti-fungals such as anidulafungin, caspofungin, micafungin sodium, amphotericin B and nystatin; and other products including lovastatin, pravastatin sodium and enzymes. It operates formulation facilities and provides contract services in fermentation, semi-synthesis, custom API development, formulation development and analytical services, with manufacturing sites in Dholka, Limbasi and Valthera, Gujarat, that hold approvals from USFDA, EU-GMP, PMDA Japan and other global regulators; Concord serves over 70 countries across North America, Europe, Japan, Latin America, Africa, Asia-Pacific, CIS and MENA regions. Recent developments include the board's approval in November 2025 to acquire 100% equity in Celliimune Biotech for entry into cell and gene therapy, a USD 1 million investment in Palvella Therapeutics for rare genetic skin disease treatments, a USD 1,500 equity investment in Stellon Biotech Inc., up to 100 million rupees investment in a solar power project for sustainability, receipt of USFDA Establishment Inspection Report and successful EU GMP, Russian GMP and other inspections at its Dholka and Valthera facilities, and commissioning of an injectable facility at Valthera.